Drug therapy doubled the time to survive for patients with an aggressive form of colon and rectal cancer, according to the late trial data published on Friday in New England Magazine for Medicine It was presented at the annual meeting of the American Association of Clinical Oncology in Chicago.
The three treatment group included a standard chemotherapy, and antibodies are called cytoximab and a Pfizer birth control pill called Praftovi, which targets a Cancer boom called Braf V600E.
Dr. Lionel Kanio Fonko, a gastroenterologist at the Mayo Clinic Comprehensive Cancer Center in Rochester, Minnesota, said that the boom appears in about 10 % of patients with colon and rectal cancer. Fonkua, who did not participate in the new experience, said patients with a mutation tend to stay for a period of less than a year after the diagnosis, and often do not respond well to standard chemotherapy treatments.
According to Pfizer, the risk of death for these patients is more than twice the comparison of those who do not have a mutation.
BAFTOVI was initially approved in 2020 for use with CETUXIMAB in this group of patients after other treatments failed. The new experiment looked at the drug group as a treatment called the first line.
Food and Drug Administration It was granted to address approval of the rapid track, such as the first line approach in December Provided that Pfizer provides additional data that confirms its effectiveness. The agency often gives rapid approval for treatments that take dangerous or life -threatening conditions, especially when there is an unacceptable medical need.
Dr. Christopher Liu, a professor of medicine at the University of Colorado Medical College, who did not participate in the research, called on the results as “very influential”.
“It is clear that patients live longer, and this represents a new level of care for this specific sub -group of patients who suffer from this specific mutation,” said Liu.
The experiment included more than 600 patients suffering from a mutation with colon and rectal cancer.
They were randomly chosen for patients to get the process of three dubbs or standard chemotherapy alone. Some patients in the last group were also given Bevasizumab, the treatment of the first line of colon and rectal cancer.
The experiment found that patients who obtained the complex treatment lived, on average, about 30 months, compared to about 15 months for those who obtained standard chemotherapy, with or without Bevasizumab.
Moreover, 47 % of patients who got composite treatment have no development after two years, which means that their cancer did not grow or spread.
Treatment was well tolerated, with no expected safety concerns that caused the investigators to be suspended from the trial.
“This is a truly wonderful discovery,” said Dr. Scott Kubitz, a professor of medical oncology at the MD Anderson Cancer Center in Texas and an investigator participating in the trial. “When we collect this with the level of chemotherapy for care, we get a very long survival for these unprecedented patients for this type of disease.”
More than 141,000 new colon and rectum cancer are diagnosed in the United States every year, making it the fourth most common cancer, according to what it said. Disease control and prevention centers. About 52,900 people are expected to die in the United States of colon and rectal cancer this year, according to American Cancer Association.
Lori Ricci, 61, from St. Louis, obtained a complex treatment in October 2023. The results of which were not included in the clinical experience analysis.
Ricci was diagnosed with colon and rectal cancer spread with a BRF mutation – a diagnosis that describes it as a “great shock”.
Previous colonoscopy did not discover cancer. By the time when it was diagnosed, the cancer has already reached the fourth stage. And eventually spread to her lungs and ovaries. Since she got composite treatment, she said that her blood tests had not shown no trace of cancer.
While she is still worrying about the return of cancer, she says she is now focusing on living completely – including water ski skiing and skiing.
She said, “I have learned somewhat to think about it as something in the trunk, not in the front seat.” “It is still somewhat similar to a time bomb inside me, but I believe that the work I did in my mental health really helped me to live with it.”
